Congratulations to Pliant Board Director Katharine Knobil, M.D. for being recognized as member of the Directors to Watch Class of 2024 by Directors & Boards magazine. This recognition highlights Katharine's significant contributions to ensuring a robust board culture and maintaining corporate governance excellence. Congrats from all of #TeamPliant! Learn more about Katharine and this recognition: https://lnkd.in/gZz9GCyd
Pliant Therapeutics
Biotechnology Research
South San Francisco, California 11,207 followers
We are transforming the lives of patients by developing best-in-class treatments for fibrotic diseases.
About us
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. At Pliant, we share a commitment and a clear passion to drive innovative science towards addressing areas of unmet medical need. Together we believe we have the power to make a difference in the lives of patients and those impacted by fibrotic diseases. We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates aimed at halting or even reversing fibrotic diseases. Pliant recognizes the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. Pliant is an equal opportunity employer and does not discriminate against any individual or potential candidate based on race, color, religion, sex, national origin, sexual preference or any other legally protected category. Pliant is located in South San Francisco, California, the birthplace of biotechnology. Proud to be a San Francisco Business Times Best Place to Work in 2023. Learn more about how we are breaking ground in the treatment of fibrotic diseases at www.PliantRx.com.
- Website
-
http://www.pliantrx.com
External link for Pliant Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2015
- Specialties
- fibrosis, integrins, muscle biology, oncology, Duchenne muscular dystrophy, Idiopathic pulmonary fibrosis, Primary sclerosing cholangitis, muscular dystrophy, Metabolic dysfunction-associated steatohepatitis, and MASH
Locations
-
Primary
Get directions
260 Littlefield Ave
South San Francisco, California 94080, US
Employees at Pliant Therapeutics
Updates
-
We are very pleased to welcome Steve Krognes to the Pliant board. Learn more about Steve: https://lnkd.in/g_AgHPMw
-
-
As part of this week’s EASL | The Home of Hepatology's International Liver Congress™, we were pleased to share preclinical and clinical data from our bexotegrast program in primary sclerosing cholangitis (PSC), including interim data from our ongoing INTEGRIS-PSC trial. https://lnkd.in/gA8XM8cK #EASLCongress #EASLNews #EASL
-
This years American Thoracic Society International Conference featured several clinical and preclinical data presentations from our bexotegrast program. Read the full release and review the presentations: https://lnkd.in/e2W3k6kF #ATS2024
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference | Pliant Therapeutics, Inc.
ir.pliantrx.com
-
Today is International Clinical Trials Day, a day to highlight the importance of clinical trials and celebrate those who bring hope to millions. From the professionals who advance clinical research and shepherd those trials to the heroic patients, all of us at Pliant recognize and celebrate the critical role each of you plays to advance research and improve patient healthcare outcomes. #ClinicalTrialsDay #CTD2024
-
-
Our CEO, Dr. Bernard Coulie, spoke with BiotechTV’s Brad Loncar to review Pliant’s progress including recent positive clinical data from an imaging trial of our lead program evaluating bexotegrast in IPF. Full interview: https://lnkd.in/gQPQckeU
Pliant's CEO on targeting integrins to treat fibrotic diseases like IPF and liver disease
biotechtv.com
-
Today we announced positive topline results from a Phase 2a imaging clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis. Learn more about these results: https://lnkd.in/e4Dw3xjf
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis | Pliant Therapeutics, Inc.
ir.pliantrx.com
-
At Pliant, we take steps to make every day Earth Day. This year our Plianteers once again scaled South San Francisco’s Sign Hill overlooking the birthplace of biotechnology to improve the mountain for all to enjoy. Thank you City of South San Francisco's Parks Division and Sign Hill Stewards for hosting us! #TeamPliant
-
-
Today we announced our presentations at the upcoming 2024 EASL | The Home of Hepatology Congress. https://lnkd.in/gA4zgttZ #EASLCongress
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™ | Pliant Therapeutics, Inc.
ir.pliantrx.com
-
Today we announced our First Quarter 2024 Financial Results and provided a company update. Review our progress to date and the milestones for 2024: https://lnkd.in/gv8rxfJM
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results | Pliant Therapeutics, Inc.
ir.pliantrx.com